title: Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD.
abstract: SERPINB3 has been found in chronic liver damage and hepatocellular carcinoma, but not in normal liver. By direct mRNA sequencing, a new SERPINB3 polymorphism (SCCA-PD) has been identified, presenting the substitution Gly351Ala in the reactive center loop of the protein. The prevalence of the SCCA-PD isoform has been found to be significantly higher in patients with cirrhosis than in patients with chronic liver disease and in normal subjects. The aim of this study was to investigate the biological and functional activity of SERPINB3 isoforms using in vitro models. HepG2 and Huh7 cells lines were transfected with plasmid vectors containing wild-type SERPINB3 or its polymorphic variant SCCA-PD and their expression at transcriptional and protein level was determined. To assess the functional activity, both recombinant proteins were produced and kinetic analysis was carried out using papain and cathepsin-L as target proteases. In addition, the inhibition of JNK kinase activity by SERPINB3 isoforms was assessed. The crystal structure of wild-type SERPINB3 at 2.7 Å resolution was used for preparation of refined 3D models of the two isoforms. The results showed that transcriptional activity and protein expression of the two isoforms were similar in both transfected cell lines. Both SERPINB3 preparations exerted a dose-dependent protease inhibitory activity, but the effect of SCCA-PD was higher than that of the wild-type isoform. This result was supported by 3D modelling, where increased hydrophobic profile of the SCCA-PD isoform, introduced by the G351A mutation, was detected. In addition, at high protein concentration, SCCA-PD revealed a 16% higher inhibitory effect on c-Jun phosphorylation by JNK1, compared with wild-type SERPINB3. In conclusion, the single amino acid substitution in the SERPINB3 reactive site loop improves the functional activity of SCCA-PD isoform. This different antiprotease activity might favor disease progression in patients carrying this polymorphism.
authors.affiliation: Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
authors.forename: Cristian
authors.initials: C
authors.lastname: Turato
authors.forename: Alessandra
authors.initials: A
authors.lastname: Biasiolo
authors.forename: Paolo
authors.initials: P
authors.lastname: Pengo
authors.forename: Vladimir
authors.initials: V
authors.lastname: Frecer
authors.forename: Santina
authors.initials: S
authors.lastname: Quarta
authors.forename: Silvano
authors.initials: S
authors.lastname: Fasolato
authors.forename: Mariagrazia
authors.initials: M
authors.lastname: Ruvoletto
authors.forename: Luca
authors.initials: L
authors.lastname: Beneduce
authors.forename: Jessica
authors.initials: J
authors.lastname: Zuin
authors.forename: Giorgio
authors.initials: G
authors.lastname: Fassina
authors.forename: Angelo
authors.initials: A
authors.lastname: Gatta
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pontisso
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics* / Q000378:metabolism*; D002460:Cell Line; D020869:Gene Expression Profiling; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D048055:Mitogen-Activated Protein Kinase 8 / Q000037:antagonists & inhibitors; D008958:Models, Molecular; D050505:Mutant Proteins / Q000235:genetics / Q000378:metabolism; D020125:Mutation, Missense; D010957:Plasmids; D017434:Protein Structure, Tertiary; D015843:Serpins / Q000235:genetics* / Q000378:metabolism*; D014162:Transfection
chemical_list: D000951:Antigens, Neoplasm; D050505:Mutant Proteins; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; D048055:Mitogen-Activated Protein Kinase 8